CSL Behring
π§πͺBelgium
Study of Safety and Efficacy of Antihemophilic Factor/Von Willebrand Factor Complex in Surgical Subjects With Von Willebrand Disease (vWD)
Phase 4
Completed
- Conditions
- Blood Coagulation DisordersBlood Platelet DisordersHematologic DiseaseVon Willebrand Disease
- First Posted Date
- 2005-09-14
- Last Posted Date
- 2011-02-11
- Lead Sponsor
- CSL Behring
- Target Recruit Count
- 30
- Registration Number
- NCT00168090
Efficacy and Safety of Intravenous Immunoglobulin IVIG-F10 in Patients With Primary Immunodeficiencies (PID)
Phase 3
Completed
- Conditions
- IgG DeficiencyCommon Variable ImmunodeficiencyAgammaglobulinemia
- First Posted Date
- 2005-09-14
- Last Posted Date
- 2011-02-11
- Lead Sponsor
- CSL Behring
- Target Recruit Count
- 42
- Registration Number
- NCT00168012
Prothrombin Complex Concentrate for Anticoagulant Reversal
Phase 3
Completed
- Conditions
- Acquired Coagulation Factor Deficiency
- First Posted Date
- 2005-09-14
- Last Posted Date
- 2011-02-11
- Lead Sponsor
- CSL Behring
- Target Recruit Count
- 40
- Registration Number
- NCT00168077
- Locations
- π¨π
Clinical Trials Registration Coordinator, Zuerich, Switzerland
π©πͺFor information on sites in Europe, please contact our clinical research team in, Marburg, Germany
Treatment of Chronic Immune Thrombocytopenic Purpura (ITP) With Intravenous Immunoglobulin IgPro10
Phase 3
Completed
- Conditions
- Immune Thrombocytopenic Purpura
- First Posted Date
- 2005-09-14
- Last Posted Date
- 2011-11-23
- Lead Sponsor
- CSL Behring
- Target Recruit Count
- 58
- Registration Number
- NCT00168038
- Locations
- π¬π§
Study Site, Taunton, United Kingdom
π·πΊStudy Site (19), St. Petersburg, Russian Federation
π·πΊStudy Site (20), St. Petersburg, Russian Federation
Efficacy and Safety of Intravenous Immunoglobulin IgPro10 in Patients With Primary Immunodeficiencies (PID)
Phase 3
Completed
- Conditions
- AgammaglobulinemiaIgG DeficiencyCommon Variable Immunodeficiency
- Interventions
- Drug: Immunoglobulins Intravenous (Human)
- First Posted Date
- 2005-09-14
- Last Posted Date
- 2012-06-06
- Lead Sponsor
- CSL Behring
- Target Recruit Count
- 89
- Registration Number
- NCT00168025
Human C1 Esterase Inhibitor (C1-INH) in Subjects With Acute Abdominal or Facial Hereditary Angioedema (HAE) Attacks
Phase 2
Completed
- Conditions
- Hereditary Angioedema
- First Posted Date
- 2005-09-14
- Last Posted Date
- 2015-03-31
- Lead Sponsor
- CSL Behring
- Target Recruit Count
- 126
- Registration Number
- NCT00168103
- Locations
- π¬π§
Study Site, London, United Kingdom
π·πΊStudy Site 1, Moscow, Russian Federation
π·πΊStudy Site 2, Moscow, Russian Federation